Research programme: DNA Ligase Antagonist - RicercaAlternative Names: Research programme: antibacterials - Ricerca
Latest Information Update: 30 Mar 2009
At a glance
- Originator Ricerca Biosciences LLC
- Developer Eli Lilly
- Class Small molecules
- Mechanism of Action DNA repair enzyme inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 20 Jan 2003 Preclinical trials in Bacterial infections in USA (unspecified route)